Jon T. Holmlund
Nessuna posizione attualmente
Profilo
Jon T.
Holmlund worked as the Medical Director at Aspire IRB LLC.
He was the Vice President-Development at Ionis Pharmaceuticals, Inc. from 1997 to 2004.
From 2004 to 2007, he served as the Chief Medical Officer & Vice President-Development at Ascenta Therapeutics, Inc. He was also a Principal at the National Cancer Institute.
Dr. Holmlund holds a doctorate degree from the State University of New York at Buffalo.
Precedenti posizioni note di Jon T. Holmlund
| Società | Posizione | Fine |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 31/12/2022 |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Chief Tech/Sci/R&D Officer | 01/11/2007 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2004 |
Aspire IRB LLC
 Aspire IRB LLC Miscellaneous Commercial ServicesCommercial Services Aspire IRB LLC operates as an independent review board that provides human subject protection oversight in clinical trials for life science companies. The private company is based in San Diego, CA and has subsidiaries in the United States. | Chief Tech/Sci/R&D Officer | - |
National Cancer Institute
 National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Corporate Officer/Principal | - |
Formazione di Jon T. Holmlund
| State University of New York at Buffalo | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| GALERA THERAPEUTICS, INC. | Health Technology |
| Aziende private | 3 |
|---|---|
Ascenta Therapeutics, Inc.
Ascenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ascenta Therapeutics, Inc. engages in the discovery and development of medicines for cancer. Its core technology consists of agents designed to re-establish the natural program of apoptosis (cell death) in abnormal cancer cells. Its has three small molecule programs against distinct apoptosis targets: Bcl-2 (AT-101 – an oral pan-Bcl2 inhibitor), IAP (AT-406 – an oral multi-IAP inhibitor) and HDM2. The company was founded by Dajun Yang, Marc E. Lippman, and Shaomeng Wang on June 5, 2006 and is headquartered in Malvern, PA. | Health Technology |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous National Cancer Institute provides healthcare services. It specializes in different cancer treatment such as adrenocortical carcinoma, anal cancer, appendix cancer, skin cancer, breast cancer, cardiac tumors, endometrial cancer, and gallbladder cancer. The company was founded in March 1937 and is headquartered in Bethesda, MD. | Miscellaneous |
Aspire IRB LLC
Aspire IRB LLC Miscellaneous Commercial ServicesCommercial Services Aspire IRB LLC operates as an independent review board that provides human subject protection oversight in clinical trials for life science companies. The private company is based in San Diego, CA and has subsidiaries in the United States. | Commercial Services |
- Borsa valori
- Insiders
- Jon T. Holmlund
